Tarsus Pharmaceuticals, Inc.正通过收购Irenix Medical及其处于后期开发阶段的资产Irx-101,积极推动其眼科护理领域的领导力战略。此举旨在强化公司在专业眼科治疗市场的布局,并获取具有潜力的创新疗法。
Tarsus Pharmaceuticals, Inc.正通过收购Irenix Medical及其处于后期开发阶段的资产Irx-101,积极推动其眼科护理领域的领导力战略。此举旨在强化公司在专业眼科治疗市场的布局,并获取具有潜力的创新疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.